Induction of Progressive Profound Hypocitraturia with Increasing Doses of Topiramate

Urology

Volumn 72, Issue 1, 2008, Pages 29-32

  Warner, Brad W ^a   LaGrange, Chad A ^a   Tucker, Tarvez ^a   Bensalem Owen, Meriem ^a   Pais Jr , Vernon M ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITRIC ACID; TOPIRAMATE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG HALF LIFE; HUMAN; HYPOCITRATURIA; KIDNEY CONCENTRATING CAPACITY; KIDNEY DISEASE; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; URINALYSIS; URINE VOLUME;

ADULT; ANTICONVULSANTS; CALCIUM; CITRIC ACID; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FRUCTOSE; HUMANS; MIDDLE AGED; MIGRAINE DISORDERS; URINARY CALCULI;

EID: 45849099105     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.01.042     Document Type: Article

References (16)

1. Brandes J.L., Saper J.R., Diamond M., et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 145 (2004) 419-420
2. Wasserstein A.G., Rak I., and Reife R.A. Nephrolithiasis during treatment with topiramate. Epilepsia 36 suppl 3 (1995) 153
3. Wasserstein A.G., Rak I., and Reife R.A. Investigation of the mechanistic basis for topiramate-associated nephrolithiasis: examination of urinary and serum constituents. Epilepsia 36 suppl 3 (1995) 153
4. Eggener S., Kim S.C., User H.M., et al. Urolithiasis associated with topiramate. Int Braz J Urol 30 (2004) 29-31
5. Kuo R.L., Moran M.E., Kim D.H., et al. Topiramate-induced nephrolithiasis. J Endourol 16 (2002) 229-231
6. Lamb E.J., Stevens P.E., and Nashef L. Topiramate increases biochemical risk of nephrolithiasis. Ann Clin Biochem 41 (2004) 166-169
7. Takhar J., and Manchanda R. Nephrolithiasis on topiramate therapy. Can J Psychiatry 45 (2000) 491-493
8. Dodgson S.J., Shank R.P., and Maryanoff B.E. Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia 41 suppl 1 (2000) 35-39
9. Welch B.J., Graybeal D., Orson W.M., et al. Biochemical and stone-risk profiles with topiramate treatment. Am J Kidney Dis 48 (2006) 555-563
10. Easterling D.E., Zakszewski T., Moyer M.D., et al. Plasma pharmacokinetics of topiramate, a new anticonvulsant in humans. [abstract]. Epilepsia 29 (1988) 662
11. Kossoff E.H., Pyzik P.L., Furth S.L., et al. Kidney stones, carbonic anhydrase inhibitors, and the ketogenic diet. Epilepsia 43 (2002) 1168-1171
12. Brown D., Zhu X.L., and Sly W.S. Localization of membrane-associated carbonic anhydrase type IV in kidney epithelial cells. Proc Natl Acad Sci U S A 87 (1990) 7457-7461
13. Hamm L.L., and Hering-Smith K.S. Pathophysiology of hypocitraturic nephrolithiasis. Endocrinol Metab Clin N Am 31 (2002) 885-893
14. Aruga S., Wehrli S., Kaissling B., et al. Chronic metabolic acidosis increases NaDC-1 mRNA and protein abundance in rat kidney. Kidney Int 58 (2000) 206-215
15. Jenkins A.D., Dousa T.P., and Smith L.H. Transport of citrate across renal brush border membrane: effects of dietary acid and alkali loading. Am J Physiol 249 (1985) F590-F595
16. Winum J.Y., Temperini C., Cheikh K.E., et al. Carbonic anhydrase inhibitors: clash with ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue. J Med Chem 49 (2006) 7024-7031